A pooled analysis of five prospective trials showed that stereotactic body radiotherapy (SBRT) was associated with a lower risk for biochemical failure over 10 years vs high-dose rate brachytherapy ...

Adding PSMA-based radioligand therapy to metastasis-directed SBRT in men with oligorecurrent prostate cancer delays progression, defined by PSMA PET/CT. As PSMA-targeting RLT improves survival ...

The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

Addition of 6 months of androgen deprivation therapy to stereotactic body radiotherapy more than doubled PFS in hormone-sensitive oligorecurrent prostate cancer. Nearly all patients treated with the ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

Stereotactic body radiotherapy as salvage therapy after radical prostatectomy was well tolerated. Toxic effects were comparable to a historical cohort of patients receiving conventionally fractionated ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...

In men with localized, intermediate-risk prostate cancer, stereotactic body radiation therapy (SBRT) was associated with less toxicity at 2 years but a higher rate of biochemical failure at 3 years ...

Disparities in guideline-concordant treatment receipt for localized prostate cancer (PCa): A SEER-based analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

The findings, published in JAMA Network Open, were reported by Cristian Udovicich of the Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada, and colleagues. The investigators ...